SISTM

Statistics in systems biology and translationnal medicine

Details

Contact

Sandrine Darmigny

Rodolphe Thiebaut

Pr. Rodolphe Thiebaut
MD, PhD, SISTM Director

Rodolphe Thiebaut is a medical doctor, with specialization in Public Health. He holds a PhD in Biostatistics from Bordeaux University.

> Read more

Objectives

The team is devoted to the development of statistical methods for the integrative analysis of data in medicine and biology. Thanks to the technological improvements, clinical and biological research is generating massive amounts of data. Of importance are the « omics » data such as genomics (gene expression) and proteomics but also other types of data, for which modern technologies have strongly increased the amount of information (e.g. medical imaging, cell counts).
This SISTM team is labelled by both Inserm and Inria.

The applications are carried out in collaboration with the Vaccine Research Institute (VRI), other teams from the center as well as the Methodological Support Unit for Clinical and Epidemiological Research (USMR) of the Bordeaux University Hospital.

The two main objectives of the SISTM team are:

  • To accelerate the development of vaccines by analyzing all the information available in early clinical trials and optimizing new trials.
  • To develop new data science approaches to analyze and model high dimensional data in small sample size studies.

Research area

The team is organized around three axes sharing a common objective. It is embarked in a double challenge of developing methods to deal with high dimensional data with low sample size and a main application for accelerating vaccine development.

Hence in Axis 1, the relevant information is extracted from big data. This information is used to estimate mechanistic model parameters in Axis 2. Mechanistic models can then be used for simulating the optimal vaccine strategies to be evaluated in the next clinical trials.

Find out more

2021 Key publications

Alexandre M, Prague M, Thiebaut R. Between-group comparison of area under the curve in clinical trials with censored follow-up: Application to HIV therapeutic vaccines. Stat Methods Med Res. 2021 Jul 4:9622802211023963. https://doi.org/10.1177/09622802211023963

Barry H, Mutua G, Kibuuka H, Anywaine Z, Sirima SB, Meda N, Anzala O, Eholie S, Betard C, Richert L, Lacabaratz C, McElrath MJ, De Rosa S, Cohen KW, Shukarev G, Robinson C, Gaddah A, Heerwegh D, Bockstal V, Luhn K, Leyssen M, Douoguih M, Thiebaut R, group EBLS. Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa. PLoS Med. 2021 Oct;18(10):e1003813. https://doi.org/10.1371/journal.pmed.1003813

Capitaine L, Genuer R, Thiebaut R. Random forests for high-dimensional longitudinal data. Stat Methods Med Res. 2021 Jan;30(1):166-84. https://doi.org/10.1177/0962280220946080

Colas C, Hejblum B, Rouillon S, Thiebaut R, Oudeyer PY, Moulin-Frier C, Prague M. EpidemiOptim: A Toolbox for the Optimization of Control Policies in Epidemiological Models. J Artif Intell Res. 2021 Jul;71:479-519. https://doi.org/10.1613/jair.1.12588

Levy Y, Lacabaratz C, Lhomme E, Wiedemann A, Bauduin C, Fenwick C, Foucat E, Surenaud M, Guillaumat L, Boilet V, Rieux V, Bouchaud O, Girard PM, Molina JM, Morlat P, Hocqueloux L, Richert L, Pantaleo G, Lelievre JD, Thiebaut R. A randomized placebo-controlled efficacy study of a prime boost therapeutic vaccination strategy in HIV-1 infected individuals: VRI02 ANRS 149 LIGHT Phase II trial. J Virol. 2021 Apr 12;95(9). https://doi.org/10.1128/jvi.02165-20

Levy Y, Wiedemann A, Hejblum BP, Durand M, Lefebvre C, Surenaud M, Lacabaratz C, Perreau M, Foucat E, Dechenaud M, Tisserand P, Blengio F, Hivert B, Gauthier M, Cervantes-Gonzalez M, Bachelet D, Laouenan C, Bouadma L, Timsit JF, Yazdanpanah Y, Pantaleo G, Hocini H, Thiebaut R, French Ccsg. CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death. iScience. 2021 Jul 23;24(7):102711. https://doi.org/10.1016/j.isci.2021.102711

Loubet P, Wittkop L, Tartour E, Parfait B, Barrou B, Blay JY, Hourmant M, Lachatre M, Laplaud DA, Laville M, Laviolle B, Lelievre JD, Morel J, Nguyen S, Spano JP, Terrier B, Thiebaut A, Viallard JF, Vrtovsnik F, de Lamballerie X, Launay O. A French cohort for assessing COVID-19 vaccine responses in specific populations. Nat Med. 2021 Jul 12;27(8):1319-21. https://doi.org/10.1038/s41591-021-01435-1

Pollard AJ, Launay O, Lelievre JD, Lacabaratz C, Grande S, Goldstein N, Robinson C, Gaddah A, Bockstal V, Wiedemann A, Leyssen M, Luhn K, Richert L, Betard C, Gibani MM, Clutterbuck EA, Snape MD, Levy Y, Douoguih M, Thiebaut R, group EEs. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2021 Apr;21(4):493-506. https://doi.org/10.1016/S1473-3099(20)30476-X

Zhang HG, Hejblum BP, Weber GM, Palmer NP, Churchill SE, Szolovits P, Murphy SN, Liao KP, Kohane IS, Cai T. ATLAS: an automated association test using probabilistically linked health records with application to genetic studies. J Am Med Inform Assoc. 2021 Nov 25;28(12):2582-92. https://doi.org/10.1093/jamia/ocab187

Prague M, Lavielle M. SAMBA: A novel method for fast automatic model building in nonlinear mixed-effects models. CPT Pharmacometrics Syst Pharmacol. 2022 Feb 1;11(2):161-72. https://doi.org/10.1002/psp4.12742

Consulter toutes les publications de l’équipe dans Oskar